2024-10-19 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**1. Performance vs. S&P 500**

Abbott Laboratories (ABT) is a multinational healthcare company that develops, manufactures, and sells a wide range of medical devices, pharmaceuticals, and nutrition products. 

- **Cumulative return:** ABT: 113.76%, S&P 500 (VOO): 137.88%
- **Lag:**  -24.12% (Relative Lag: 17.29%)

**2. Recent Price Movements**

- **Closing Price:** $119.39
- **5-day Moving Average:** $117.68
- **20-day Moving Average:** $114.85
- **60-day Moving Average:** $112.91

**3. Technical Indicators**

- **RSI:** 72.95 (Overbought territory, indicating potential for a pullback)
- **PPO:** 0.38 (Positive, suggesting upward momentum)
- **Delta_Previous_Relative_Divergence:** 3.39 (Short-term upward trend, indicating potential for further gains)
- **Expected Return:** 0.0% (Estimated long-term (2+ years) expected return relative to the S&P 500)

**4. Recent Earnings and Outlook**

| Date | EPS | Revenue |
|---|---|---|
| 2024-07-31 | 0.74 | 10.38 B$ |
| 2024-05-02 | 0.7 | 9.96 B$ |
| 2023-11-01 | 0.82 | 10.14 B$ |
| 2023-08-03 | 0.79 | 9.98 B$ |
| 2024-07-31 | 0.79 | 9.98 B$ |

- **Most recent earnings (Q2 2024):** EPS of $0.74 beat analyst estimates of $0.72, while revenue of $10.38B missed estimates of $10.46B. 
- **Outlook:** Analysts are expecting continued growth in ABT's diagnostics and nutrition segments, driven by increased demand and new product launches.

**5. News and Recent Issues**

- **Recent Market Outlook:** ABT's stock has been performing relatively well despite the broader market downturn. Investors continue to see value in ABT's diverse product portfolio and strong dividend yield.
- **Analyst Opinions:** Many analysts remain optimistic about ABT's long-term prospects, citing its strong financial position, consistent earnings growth, and commitment to research and development.
- **Performance Highlights:** ABT's shares have outperformed the S&P 500 over the past year, driven by strong earnings and a focus on innovation. 

**6. Overall Analysis**

ABT is a well-established healthcare company with a strong track record of consistent earnings growth and dividend payments. However, its recent performance has lagged the S&P 500, and its current price may be overvalued based on technical indicators. While ABT's long-term outlook remains positive, investors should be aware of the potential for near-term price volatility.

**7. Recommendation**

For investors seeking a long-term investment with a focus on dividends and growth, ABT may be a good consideration. However, current valuations and market sentiment suggest caution in the near term. Further monitoring of key financial metrics and the company's strategic initiatives is advised. 
